Incidence and severity of sensory neuropathy (SN) with bevacizumab (B) added to dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound (nab) paclitaxel (P) in patients (pts) with early stage breast cancer (BC) Meeting Abstract


Authors: Sierecki, M. R.; Rugo, H. S.; McArthur, H. L.; Traina, T. A.; Paulson, M.; Rourke, M.; Norton, L.; Seidman, A. D.; Hudis, C. A.; Dickler, M. N.
Abstract Title: Incidence and severity of sensory neuropathy (SN) with bevacizumab (B) added to dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound (nab) paclitaxel (P) in patients (pts) with early stage breast cancer (BC)
Meeting Title: 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 26
Issue: 15 Suppl.
Meeting Dates: 2008 May 30-Jun 3
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2008-05-20
Start Page: 28s
Language: English
ACCESSION: WOS:000208457400110
DOI: 10.1200/jco.2008.26.15_suppl.589
PROVIDER: wos
Notes: Meeting Abstract: 589-- Source: Wos
Altmetric Score
MSK Authors
  1. Andrew D Seidman
    244 Seidman
  2. Clifford Hudis
    840 Hudis
  3. Larry Norton
    563 Norton
  4. Maura N Dickler
    237 Dickler
  5. Tiffany A Traina
    153 Traina